Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro.

Literature DB >> 20617511

Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro.

Mingqian Feng, Heungnam Kim, Yen Phung, Mitchell Ho.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 20617511 PMCID： PMC2995816 DOI： 10.1002/ijc.25549

Source DB: PubMed Journal: Int J Cancer ISSN： 0020-7136 Impact factor: 7.396

× No keyword cloud information.

5 in total

1. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.

Authors: Mariana I Capurro; Yun-Yan Xiang; Corrinne Lobe; Jorge Filmus
Journal: Cancer Res Date: 2005-07-15 Impact factor: 12.701

2. Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth.

Authors: Mariana I Capurro; Wen Shi; Shaifali Sandal; Jorge Filmus
Journal: J Biol Chem Date: 2005-10-14 Impact factor: 5.157

3. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.

Authors: Yoshitaka Hippo; Kiyotaka Watanabe; Akira Watanabe; Yutaka Midorikawa; Shogo Yamamoto; Sigeo Ihara; Susumu Tokita; Hiroko Iwanari; Yukio Ito; Kiyotaka Nakano; Jun-ichi Nezu; Hiroyuki Tsunoda; Takeshi Yoshino; Iwao Ohizumi; Masayuki Tsuchiya; Shin Ohnishi; Masatoshi Makuuchi; Takao Hamakubo; Tatsuhiko Kodama; Hiroyuki Aburatani
Journal: Cancer Res Date: 2004-04-01 Impact factor: 12.701

4. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.

Authors: Sandra I Zittermann; Mariana I Capurro; Wen Shi; Jorge Filmus
Journal: Int J Cancer Date: 2010-03-15 Impact factor: 7.396

5. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner.

Authors: A D Gonzalez; M Kaya; W Shi; H Song; J R Testa; L Z Penn; J Filmus
Journal: J Cell Biol Date: 1998-06-15 Impact factor: 10.539

5 in total

21 in total

1. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.

Authors: Na Li; Liwen Wei; Xiaoyu Liu; Hongjun Bai; Yvonne Ye; Dan Li; Nan Li; Ulrich Baxa; Qun Wang; Ling Lv; Yun Chen; Mingqian Feng; Byungkook Lee; Wei Gao; Mitchell Ho
Journal: Hepatology Date: 2019-05-24 Impact factor: 17.425

2. Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway.

Authors: Dolores Fernández; Macarena Guereño; María Amparo Lago Huvelle; Magalí Cercato; María Giselle Peters
Journal: J Cancer Res Clin Oncol Date: 2018-09-28 Impact factor: 4.553

3. Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study.

Authors: Dina Sabry; Omayma O Abdelaleem; Amani M El Amin Ali; Rehab A Mohammed; Nehal D Abdel-Hameed; Amira Hassouna; Warda A Khalifa
Journal: Mol Biol Rep Date: 2019-02-01 Impact factor: 2.316

Review 4. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.

Authors: Mitchell Ho
Journal: BioDrugs Date: 2011-10-01 Impact factor: 5.807

5. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.

Authors: Yen Phung; Wei Gao; Yan-Gao Man; Satoshi Nagata; Mitchell Ho
Journal: MAbs Date: 2012-07-23 Impact factor: 5.857

Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro.

1. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.

2. Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth.

3. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.

4. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.

5. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner.

1. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.

2. Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway.

3. Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study.

Review 4. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.

5. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.

Review 6. Glypican-3: a new target for cancer immunotherapy.

Review 7. Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.

Review 8. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.

9. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.

10. Two functional domains in C. elegans glypican LON-2 can independently inhibit BMP-like signaling.